Findings from the KOMET-001 study of ziftomenib in patients with NPM1-mutated AML скачать в хорошем качестве

Findings from the KOMET-001 study of ziftomenib in patients with NPM1-mutated AML

Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the promising results of the Phase Ib/II KOMET-001 study (NCT04067336) of ziftomenib in patients with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (AML). Dr Fathi highlights encouraging response rates and a tolerable toxicity profile, which he hopes will lead to the approval of this agent later this year. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.